Related Experiment Video

Updated: Jul 14, 2026

Cell Death Associated with Abnormal Mitosis Observed by Confocal Imaging in Live Cancer Cells
15:53

Cell Death Associated with Abnormal Mitosis Observed by Confocal Imaging in Live Cancer Cells

Published on: August 21, 2013

[Inhibitory effect of 5-aminoisoquinolinone on PARP activity in colon carcinoma cell line HT-29]

Lan-Xiang Hao1, Ya-Lan Wang, Li Cai

  • 1Department of Pathology,Chongqing Medical University, Chongqing, 400016, P. R. China.

AI Zheng = Aizheng = Chinese Journal of Cancer
|June 15, 2007
PubMed
Abstract

Insights

Poly(adenosine 5'-diphosphate ribose) polymerase (PARP) inhibitor 5-Aminoisoquinolinone (5-AIQ) reduces colon cancer cell adhesion. 5-AIQ also decreases PARP, P-selectin, and ICAM-1 expression in HT-29 cells.

Area of Science:

  • Oncology
  • Molecular Biology
  • Biochemistry

Background:

  • Poly(adenosine 5'-diphosphate ribose) polymerase (PARP) is implicated in inflammation, but its role in tumor progression remains unclear.
  • The study focuses on the colon carcinoma cell line HT-29 to elucidate the biological functions of 5-AIQ-induced PARP inhibition.

Purpose of the Study:

  • To investigate the role of 5-AIQ-induced PARP inhibition in colon carcinoma.
  • To assess the effect of 5-AIQ on the adhesion of HT-29 cells to human umbilical vein endothelial cells (HUVECs).
  • To examine the impact of 5-AIQ on the expression of PAR, P-selectin, and ICAM-1 in HT-29 cells.

Main Methods:

  • SP immunohistochemistry and double immunofluorescence staining were used to detect PAR expression and its co-expression with P-selectin and ICAM-1 in colorectal carcinoma and adjacent normal mucosa.
  • Adhesion assays were performed to quantify the adhesion of HT-29 cells to HUVECs after treatment with varying concentrations of 5-AIQ.
  • Western blotting or similar techniques were employed to measure protein levels of PAR, P-selectin, and ICAM-1 in treated and untreated HT-29 cells.

Main Results:

  • PAR expression was significantly elevated in colorectal carcinoma tissues compared to normal mucosa and correlated with metastatic status.
  • PAR expression was found to be correlated with P-selectin and ICAM-1 expression in colorectal carcinoma.
  • Treatment with 5-AIQ significantly reduced the adhesion of HT-29 cells to HUVECs in a dose-dependent manner.
  • 5-AIQ treatment led to a significant decrease in the protein levels of PAR, P-selectin, and ICAM-1 in HT-29 cells.

Conclusions:

  • PARP activity is enhanced in colorectal carcinoma, suggesting its potential role in cancer development.
  • The PARP inhibitor 5-AIQ effectively inhibits the adhesion of colon carcinoma cells (HT-29) to endothelial cells (HUVECs).
  • 5-AIQ treatment reduces the expression of PAR, P-selectin, and ICAM-1 in HT-29 cells, indicating a potential therapeutic mechanism.

More Related Videos

Visualization and Quantitative Analysis of Genotoxin-Induced PARP1/PARP2 Activation in Cells Using a Fluorescent Fusion Protein-Based Reporter07:53

Visualization and Quantitative Analysis of Genotoxin-Induced PARP1/PARP2 Activation in Cells Using a Fluorescent Fusion Protein-Based Reporter

Published on: April 17, 2026

Assessment of Global DNA Double-Strand End Resection using BrdU-DNA Labeling coupled with Cell Cycle Discrimination Imaging06:44

Assessment of Global DNA Double-Strand End Resection using BrdU-DNA Labeling coupled with Cell Cycle Discrimination Imaging

Published on: April 28, 2021

Related Concept Videos

Inhibitors of Bacterial DNA Synthesis01:28

Inhibitors of Bacterial DNA Synthesis

Bacterial pathogens depend on precise and efficient DNA replication to sustain infection. Two type II topoisomerases—DNA gyrase and topoisomerase IV—are critical to this process, as they resolve DNA supercoiling and unlink chromosomes during replication. Fluoroquinolones, synthetic derivatives of quinolones, exploit this mechanism by stabilizing the transient DNA–enzyme cleavage complex, preventing strand religation, and causing lethal double-strand breaks. These antibiotics are selectively...
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
Inhibition of CDK Activity02:34

Inhibition of CDK Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
Drugs that Destabilize Microtubules01:10

Drugs that Destabilize Microtubules

Microtubules are dynamic structures and can be regulated by microtubule targeting agents (MTAs). Microtubule destabilizing drugs are a class of MTAs that destabilize and prevent microtubules' polymerization. Both natural and synthetic chemicals can be found under this class of drugs. Vincristine and vinblastine, two vinca alkaloids, and colchicine were among the first to be discovered. These drugs can affect cells in various ways, either by inducing a change in cell morphology, preventing...
Drugs that Stabilize Microtubules01:15

Drugs that Stabilize Microtubules

Microtubules are dynamic structures that undergo cycles of catastrophe and rescue. The microtubules play a central role in cell division by forming the spindle apparatus for segregating the chromosomes. This makes them ideal targets for regulating dividing cells in tumors and malignant cancer cells. Microtubule stabilizing drugs help stabilize the microtubule formation and promote its polymerization. Paclitaxel was the first microtubule stabilizing agent used as anticancer drug in chemotherapy...